Skip to evidence report

FIB.adventitial.complement_angiocrine: Studies — page 13

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

State · 5,164 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 12,001–12,313 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for FIB.adventitial.complement_angiocrine
#Trait / studyIndividual trait IDMean IC score
12001Current employment status - In paid employment or self-employed | EmploymentUKBB000001583.31e-06
12002CDC37/PPP1R12A ratioGCST903139343.31e-06
12003CDKN1A/TACC3 ratioGCST903139753.28e-06
12004OSM levelsGCST904701333.26e-06
12005Cholesteryl esters to total lipids in large HDL percentage (UKB data field 23636)GCST902697333.25e-06
12006PPME1/PSMD9 ratioGCST903157053.25e-06
12007IFNG levelsGCST904695153.24e-06
12008FOLR2 levelsGCST904692603.23e-06
12009CSF1/IFNGR1 ratioGCST903142833.22e-06
12010Other disorders of fluid, electrolyte and acid-base balanceFING000010273.18e-06
12011Mean corpuscular hemoglobinGCST0046303.18e-06
12012DBNL/DNAJA2 ratioGCST903144153.15e-06
12013CD1C/CD207 ratioGCST903137453.14e-06
12014HTRA2/SIAE ratioGCST903150973.14e-06
12015Other and unspecified nerve root and plexus disorders, also in other diseasesFING000009443.12e-06
12016Concentration of LDL particlesGCST904984133.11e-06
12017Suffer from 'nerves' | Mental healthUKBB000007993.10e-06
12018BST2 levelsGCST904684753.09e-06
12019Mean corpuscular hemoglobinGCST900023903.09e-06
12020Saturated fatty acid levelsGCST900929803.07e-06
12021CD58/IFNGR1 ratioGCST903138493.04e-06
12022Omega-3 fatty acids to total fatty acids percentageGCST905024603.04e-06
12023APP/HBEGF ratioGCST903133243.03e-06
12024SIGLEC1 levelsGCST904706323.02e-06
12025F9/FURIN ratioGCST903147473.01e-06
12026ULBP2 levelsGCST904710083.00e-06
12027Total triglycerides levelsGCST900929922.99e-06
12028Mouth/teeth dental problems - Mouth ulcers | MouthUKBB000004882.97e-06
12029Symbol digit substitution test performance (baseline)GCST905658412.96e-06
12030CR1 levelsGCST904688512.96e-06
12031Erythematosquamous dermatosis (PheCode 690)GCST904761702.94e-06
12032KLRD1/LY9 ratioGCST903152612.94e-06
12033Total fatty acid levelsGCST900929872.90e-06
12034Recent feelings of foreboding | AnxietyUKBB000007382.86e-06
12035Loneliness, isolation | Mental healthUKBB000004082.86e-06
12036FCRL6/KLRD1 ratioGCST903148072.82e-06
12037Mean corpuscular haemoglobin (UKB data field 30050)GCST904680842.79e-06
12038RARRES2/ST6GAL1 ratioGCST903157592.76e-06
12039Red cell distribution widthGCST900259882.75e-06
12040Triglycerides in very small VLDLGCST905008852.73e-06
12041Free cholesterol to total lipids in very large VLDL percentage (UKB data field 23587)GCST902696842.72e-06
12042eosinophil (absolute count, maximum, inv-norm transformed)GCST904752882.72e-06
12043IL12RB1 levelsGCST904695502.71e-06
12044Oxalate (ethanedioate) levelsGCST901996722.69e-06
12045neutrophil (fraction, mean, inv-norm transformed)GCST904755382.66e-06
12046Reason for reducing amount of alcohol drunk - Other reason | AlcoholUKBB000007352.65e-06
12047Types of transport used (excluding work) - Cycle | Physical activityUKBB000008772.64e-06
12048KLRD1 levelsGCST904697112.64e-06
12049Concentration of large LDL particlesGCST904980372.62e-06
12050ADH4/SCLY ratioGCST903131952.61e-06
12051Total fatty acid levelsGCST905027102.61e-06
12052ObesityFING000008952.58e-06
12053Saturated fatty acids to total fatty acids percentageGCST904999582.55e-06
12054Takes medication for Skin condition (ex. Eczema, Psoriasis)?GCST904752752.53e-06
12055Alcohol drinker status - Current | AlcoholUKBB000000212.51e-06
12056Phospholipids to total lipids ratio in medium VLDLGCST900929252.50e-06
12057FABP3 levelsGCST904691752.48e-06
12058Triglyceride levels in small LDLGCST900929662.47e-06
12059C1RL levelsGCST904684922.43e-06
12060SDC4 levelsGCST904705592.42e-06
12061Alzheimer's disease (MTAG)GCST904490582.40e-06
12062Alzheimer's disease or family history of Alzheimer's diseaseGCST900128772.36e-06
12063CLPP levelsGCST904687852.34e-06
12064HypothyroidismGCST903193202.30e-06
12065HypothyroidismGCST904681382.30e-06
12066Treatment or medication use - insulin product (UKB data field 20003_1140883066)GCST900422262.29e-06
12067F-fatty/dairy food liking (derived food-liking factor)GCST900947602.28e-06
12068Pure hypercholesterolaemiaFING000012302.27e-06
12069Total lipid levels in small HDLGCST900929502.22e-06
12070Omega-3 fatty acid levelsGCST905020552.18e-06
12071CDKN1A/TXLNA ratioGCST903139792.15e-06
12072F-fruit liking (derived food-liking factor)GCST900947672.15e-06
12073Basophil percentage of white cellsGCST900023802.11e-06
12074Cholelithiasis | Disorders of gallbladder, biliary tract and pancreasUKBB000001322.09e-06
12075Cholesteryl esters to total lipids ratio in small LDLGCST900929592.07e-06
12076Alzheimer's disease or family history of Alzheimer's diseaseGCST0073202.07e-06
12077Degree of unsaturationGCST905027462.06e-06
12078Clonal haematopoiesis of indeterminate potential (with or without mosaic chromosomal alteration)GCST901652672.04e-06
12079mean corpuscular volume (MCV, maximum, inv-norm transformed)GCST904754662.03e-06
12080PLXNB2/SEMA7A ratioGCST903156922.02e-06
120813-methyl-2-oxobutyrate levelsGCST901996772.02e-06
12082AIF1 levelsGCST904682671.95e-06
12083Pregnenolone sulfate levelsGCST901998731.92e-06
12084Chronic sinusitis (PheCode 475)GCST904760201.89e-06
12085Crohn's diseaseGCST904753181.88e-06
12086Triglyceride levels in IDLGCST900928411.88e-06
12087CLC levelsGCST904687621.85e-06
12088Cholelithiasis | digestiveUKBB000001311.83e-06
12089AK1/PEBP1 ratioGCST903132251.82e-06
12090FCRL1/TCL1A ratioGCST903147951.80e-06
12091Addison's diseaseGCST900118711.75e-06
12092A1BG levelsGCST904681851.75e-06
12093LRTM2 levelsGCST904698081.74e-06
12094Pain in joint (PheCode 745)GCST904762621.73e-06
12095Alzheimer's disease (late onset)GCST0022451.72e-06
12096F2R/SPINT2 ratioGCST903147371.70e-06
12097Triglyceride levels in small VLDLGCST900929781.70e-06
12098PCDH17 levelsGCST904701691.68e-06
12099Basophil countGCST900259971.67e-06
12100Red cell distribution widthGCST0068041.67e-06
12101Triglycerides x anxiety interaction (2df test)GCST905706771.67e-06
12102Mean corpuscular volume | Blood countUKBB000004491.66e-06
12103Cigarettes smoked per day (MTAG)GCST901791511.64e-06
12104Remnant cholesterol (non-HDL, non-LDL -cholesterol)GCST904993401.64e-06
12105CLEC1A/CLEC7A ratioGCST903140831.62e-06
12106RARRES2 levelsGCST904704281.61e-06
12107Overweight, obesity and other hyperalimentation | endocrine/metabolicUKBB000006221.59e-06
12108Ectropion or entropion (PheCode 374.1)GCST904758911.54e-06
12109Average diameter for LDL particlesGCST904984581.52e-06
12110CD22/FOLR2 ratioGCST903137581.49e-06
12111Cholesteryl Esters in Medium LDLGCST904987391.48e-06
12112KLRB1/KLRD1 ratioGCST903152601.48e-06
12113CRLF1 levelsGCST904688681.48e-06
12114MBL2 levelsGCST904698681.45e-06
12115Phospholipids to total lipids ratio in small LDLGCST900929651.43e-06
12116Saturated fatty acids to total fatty acids percentage (UKB data field 23455)GCST902695521.42e-06
12117red cell diameter width (RDW, mean, inv-norm transformed)GCST904763611.41e-06
12118Pyruvate levelsGCST900929421.38e-06
12119ADH4/DCXR ratioGCST903131901.38e-06
12120Red cell distribution widthGCST0046211.37e-06
12121SarcoidosisGCST905034831.37e-06
12122Spondylopathies (FG)FING000013261.35e-06
12123Obesity | endocrine/metabolicUKBB000005441.35e-06
12124Omega-6 fatty acids to total fatty acids percentageGCST905021211.35e-06
12125CD74/TIMD4 ratioGCST903138961.31e-06
12126Red cell distribution widthGCST900024041.29e-06
12127Obesity | Obesity and other hyperalimentationUKBB000005451.27e-06
12128Triglycerides in very large VLDLGCST905006711.23e-06
12129Ratio of omega-6 fatty acids to total fatty acidsGCST900929351.20e-06
12130MelanomaGCST900118091.19e-06
12131HNRNPK/USP8 ratioGCST903150701.18e-06
12132CD300E levelsGCST904686211.15e-06
12133Cholesterol to total lipids ratio in small HDLGCST900929451.14e-06
12134CHIT1 levelsGCST904687441.09e-06
12135ALB/Globulin ratioUKBB000000201.01e-06
12136Phospholipids to Total Lipids in Small HDL percentageGCST904994949.84e-07
12137ACY3 levelsGCST904682139.82e-07
12138KLKB1 levelsGCST904697089.72e-07
12139SCGB3A2 levelsGCST904705439.54e-07
12140IL1R1/IL1RN ratioGCST903151589.36e-07
12141Chronic obstructive pulmonary disease in current smokersGCST900165939.23e-07
12142Total lipid levels in medium VLDLGCST900929229.06e-07
12143neutrophil (fraction, maximum, inv-norm transformed)GCST904755358.65e-07
12144Biological Sibling: Cancer, SkinGCST904763698.60e-07
12145ADGRE2 levelsGCST904682378.44e-07
12146LDLR levelsGCST904697508.25e-07
12147BCAM/SEMA7A ratioGCST903134768.20e-07
12148Phospholipids in medium LDLGCST904988328.08e-07
12149GP1BA/SDC4 ratioGCST903149577.90e-07
12150KIFBP/LYN ratioGCST903152467.88e-07
12151IL6 levelsGCST904696047.86e-07
12152F-cake/biscuits liking (derived food-liking factor)GCST900947227.83e-07
12153Omega-3 fatty acids to total fatty acids percentageGCST905020877.48e-07
121541-stearoylglycerophosphoethanolamine levelsGCST902437807.36e-07
12155MEP1A levelsGCST904698877.35e-07
12156Takes medication for Thyroid problems?GCST904752777.31e-07
12157Mineral and other dietary supplements - Calcium | MedicationUKBB000004717.28e-07
12158Type 1 diabetesGCST904320667.13e-07
12159lymphocyte (fraction, maximum, inv-norm transformed)GCST904754327.11e-07
12160Saturated fatty acids levelsGCST904999537.03e-07
12161Free cholesterol to total lipids ratio in very small VLDLGCST900930336.96e-07
12162SDC4/SEMA4D ratioGCST903158186.90e-07
12163Free cholesterol to total lipids ratio in small LDLGCST900929616.77e-07
12164Cholesteryl esters to total lipids ratio in small HDLGCST900929476.76e-07
12165mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST904754466.43e-07
12166Glutamine levelsGCST904972826.42e-07
12167Mean corpuscular volumeGCST0046026.28e-07
12168F-fatty/salty food liking (derived food-liking factor)GCST900947596.28e-07
12169KLK13 levelsGCST904696996.15e-07
12170TCL1A/TNFRSF13C ratioGCST903159126.00e-07
12171BST2/CEACAM1 ratioGCST903135375.70e-07
12172CSF3 levelsGCST904688865.60e-07
12173CD300C levelsGCST904686205.59e-07
12174Cholesterol to total lipids ratio in large VLDLGCST900928695.57e-07
12175Cholesterol to total lipids ratio in medium VLDLGCST900929175.50e-07
12176PDCD1/TNFRSF9 ratioGCST903156115.42e-07
12177Mean corpuscular haemoglobin | Blood countUKBB000004475.36e-07
12178Free cholesterol to total lipids ratio in small VLDLGCST900929735.06e-07
12179Basophil percentage of white cellsGCST0046315.04e-07
12180Thyroid problemsGCST904752764.94e-07
12181Triglyceride levels in medium HDLGCST900929024.85e-07
12182HBEGF/SDC4 ratioGCST903150374.76e-07
12183Acute upper respiratory infectionsFING000000344.66e-07
12184NFATC3 levelsGCST904700344.59e-07
12185GBP1 levelsGCST904693114.56e-07
12186Monounsaturated fatty acid levelsGCST900929284.52e-07
12187Operation code - cholecystectomy/gall bladder removal | OperationsUKBB000005544.47e-07
12188CD164/CD99 ratioGCST903137404.40e-07
12189PTPRR levelsGCST904703864.39e-07
12190Irritable bowel syndromeGCST900165644.29e-07
12191F-cheese liking (derived food-liking factor)GCST900947294.20e-07
12192BCAM/LGALS4 ratioGCST903134734.05e-07
12193CD27/NECTIN4 ratioGCST903137754.03e-07
12194Phospholipid levels in small HDLGCST900929523.97e-07
12195CDH2 levelsGCST904686733.93e-07
12196Cholesteryl esters to total lipids ratio in small VLDLGCST900929713.69e-07
12197LCN2 levelsGCST904697473.67e-07
12198CCN2/HBEGF ratioGCST903137133.58e-07
12199Red cell distribution widthGCST900023693.57e-07
12200lymphocyte (fraction, mean, inv-norm transformed)GCST904754353.56e-07
12201Basophill percentage | Blood countUKBB000000873.53e-07
12202IL18BP/ROR1 ratioGCST903151553.51e-07
12203IDP dMRI TBSS ISOVF Genu of corpus callosumGCST900044793.47e-07
12204Schizophrenia or delusion (more control exclusions)FING000012783.44e-07
12205CD63 levelsGCST904686423.39e-07
12206Positional arithmetic | Fluid intelligence / reasoningUKBB000006543.37e-07
12207Triglyceride levels in HDLGCST900928293.22e-07
12208CD163/FOLR2 ratioGCST903137343.20e-07
12209IL22RA2 levelsGCST900906993.20e-07
12210Occupational attainmentGCST901022533.16e-07
12211Linoleic acid to total fatty acids percentageGCST905023203.13e-07
12212Other diseases of upper respiratory tractFING000010123.00e-07
12213Ulcerative ileocolitisFING000013922.90e-07
12214CD163/DSC2 ratioGCST903137332.87e-07
12215White blood cell count (basophil)GCST0046182.80e-07
12216Mean corpuscular volumeGCST900187462.67e-07
12217Omega-3 fatty acids to Omega-6 fatty acids ratioGCST905020742.64e-07
12218ICAM1/REG1A ratioGCST903151142.64e-07
12219REST UKBBICA NODEamps25 0001GCST903854842.61e-07
12220Cholesteryl esters to total lipids ratio in large HDLGCST900928472.55e-07
12221ADAM8 levelsGCST904682202.51e-07
12222FAM177A1 levelsGCST902424582.49e-07
12223Omega-3 fatty acids to total fatty acids percentageGCST905020812.45e-07
12224mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed)GCST904754422.42e-07
12225ADH4/SORD ratioGCST903131962.42e-07
12226IL17RB levelsGCST904695632.41e-07
12227ARSA/CD164 ratioGCST903133512.39e-07
12228ESAM/THPO ratioGCST903147192.39e-07
12229FCAR levelsGCST904691972.36e-07
12230MILR1 levelsGCST904699072.34e-07
12231GYS1/TIA1 ratioGCST903150042.31e-07
12232ADGRE5 levelsGCST904682382.12e-07
12233Disorders of skin appendagesFING000004602.10e-07
12234PLXNB2 levelsGCST904702662.06e-07
12235Triglycerides to Total Lipids in Large HDL percentageGCST904978962.03e-07
12236Physical activity (Total log acceleration 10pm-12am)GCST900614201.96e-07
12237FCGR2B levelsGCST904692011.96e-07
12238LYVE1 levelsGCST904698321.82e-07
12239Hard cheese likingGCST900947781.81e-07
12240EFNA4 levelsGCST904690811.70e-07
12241DLL1/IL18BP ratioGCST903144951.67e-07
12242Squamous cell neoplasms and carcinomas of the skin, excluding all cancers (controls excluding all cancers)FING000013301.64e-07
12243CHI3L1/PRSS8 ratioGCST903140441.57e-07
12244Immature fraction of reticulocytesGCST0046281.56e-07
12245Irritable bowel syndrome mixed subtypeGCST902439591.55e-07
12246Provencibacterium massiliense abundance in stoolGCST900325271.49e-07
12247FAM3B/FUT3_FUT5 ratioGCST903147771.43e-07
12248ACP6 levelsGCST904682041.41e-07
12249red cell diameter width (RDW, maximum, inv-norm transformed)GCST904763571.39e-07
12250Skin and soft tissue infectionsGCST900134111.33e-07
12251CLEC4C levelsGCST904687721.31e-07
12252TSPAN1 levelsGCST904709781.27e-07
12253IL1RN/LGALS9 ratioGCST903151601.26e-07
12254OSCAR/TNFRSF14 ratioGCST903155881.23e-07
12255Triglycerides to total lipids ratio in medium VLDLGCST900929271.21e-07
12256CST7 levelsGCST904688971.20e-07
12257CD163/IL18BP ratioGCST903137361.07e-07
12258ADA2 levelsGCST904682151.05e-07
12259Triglyceride levels in very small VLDLGCST900930381.02e-07
12260GALNT5 levelsGCST904692989.99e-08
12261Triglycerides to total lipids ratio in small VLDLGCST900929799.72e-08
12262BSG/LY9 ratioGCST903135348.72e-08
12263MAMDC4 levelsGCST904698428.66e-08
12264Cholesterol to total lipids ratio in small VLDLGCST900929698.38e-08
12265SERPINA7 levelsGCST904705878.13e-08
12266Other and unspecified rosaceaFING000009517.43e-08
12267Urine 3-hydroxyindolin-2-one sulfate levels in chronic kidney diseaseGCST902645087.39e-08
12268CFHR4 levelsGCST904687276.72e-08
12269Free cholesterol to total lipids ratio in medium VLDLGCST900929216.54e-08
12270ADAM15 levelsGCST904682176.09e-08
12271Free cholesterol levels in very large HDLGCST901326806.01e-08
12272Alzheimer's diseaseGCST900271585.62e-08
12273KEL levelsGCST904696734.92e-08
12274CD163/ICAM1 ratioGCST903137354.91e-08
12275CXCL11/SDC4 ratioGCST903143364.18e-08
12276Breakthrough COVID-19 susceptibility after at least one dose of a COVID-19 vaccineGCST904486954.06e-08
12277CD48 levelsGCST904686353.61e-08
12278Omega-3 fatty acids to Omega-6 fatty acids ratioGCST905020683.13e-08
12279CLEC1A levelsGCST904687672.94e-08
12280Clonal hematopoiesis (overall)GCST904353532.76e-08
12281DSG3/NECTIN4 ratioGCST903145602.49e-08
12282Red blood cell (erythrocyte) distribution width | Blood countUKBB000007482.43e-08
12283PRSS27 levelsGCST904703422.42e-08
12284ICAM3 levelsGCST904695002.25e-08
12285IL27 levelsGCST904690602.24e-08
12286CEP43/TIA1 ratioGCST903140211.88e-08
12287Red blood cell erythrocyte distribution width (UKB data field 30070)GCST904680991.78e-08
12288Malignant melanoma, excluding all cancers (controls excluding all cancers)FING000007501.75e-08
12289Etiocholanolone glucuronide levelsGCST901999641.64e-08
12290MCTS1 levelsGCST904698741.64e-08
12291CLEC4G/KEL ratioGCST903141191.62e-08
12292C-reactive protein levels (UKB data field 30710)GCST904680641.58e-08
12293SEMA4C levelsGCST904705721.53e-08
12294CLEC4G levelsGCST904687741.48e-08
12295Cake icing likingGCST900947231.46e-08
12296C1S levelsGCST904684941.34e-08
12297IL18 levelsGCST904695671.20e-08
12298EPHB6 levelsGCST904691331.06e-08
12299Omega-3 fatty acids to total fatty acids percentageGCST905024481.05e-08
12300FCGR2A levelsGCST904692008.53e-09
12301T1 CAT GM unnormalised volumeGCST903839828.16e-09
12302DSC2 levelsGCST904690407.43e-09
12303C-reactive protein | Blood biochemistryUKBB000001136.48e-09
12304IL1RN levelsGCST904695765.32e-09
12305Omega-3 fatty acids to Omega-6 fatty acids ratioGCST905023964.65e-09
12306Other follicular disordersFING000010502.52e-09
12307Malignant melanoma of skin, excluding all cancers (controls excluding all cancers)FING000007491.48e-09
12308CD74/IL18BP ratioGCST903138921.41e-09
12309APBB1IP/POLR2F ratioGCST903133001.39e-09
12310SCARB2 levelsGCST904705351.35e-09
12311VMO1 levelsGCST904710421.20e-09
12312LY9 levelsGCST904698241.44e-11
12313GHRL levelsGCST904693418.51e-12